Physician profile
William Sheinbaum
NPI 1336112564
$2,237.87
in general payments reported to CMS, 2019-2025
17 companies · $197 in 2025
The $197 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $780 · 2020: $85.63 · 2021: $115 · 2022: $337 · 2023: $237 · 2024: $487 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $920.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $772.04 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $356.52 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $203.34 | 2019-2023 | |
| Medtronic, INC. | $155.74 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $148.73 | 2024-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $132.40 | 2022-2024 | Watchman Flx |
| Cardiofocus, INC. | $122.50 | 2019 | |
| Amgen INC. | $94.31 | 2019-2025 | Repatha, Repatha |
| Philips North America LLC | $52.16 | 2024 | (Cm9) Amb Mon & Diag Und |
| Novo Nordisk INC | $47.02 | 2021-2025 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $28.29 | 2020-2024 | Farxiga |
| Abbvie INC. | $27.06 | 2023 | Durysta |
| Regeneron Healthcare Solutions, INC. | $26.50 | 2019 | |
| Pfizer INC. | $24.66 | 2025 | |
| Amarin Pharma, INC. | $18.95 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $15.32 | 2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Sheinbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.